Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MSFT -7.61META 3.94BKNG 1.55HMP.TO 0SPGP 0.13ZUQ.TO -0.39NVDA -3.18GL 1.93
Daily Stock Opinions and Ratings
The ultimate 360° Tracker Your financial life in one place, automatically
Stockchase Opinions

Bruce CooperStressgen Biotechnologies CorpSSB.TOBUYDec 08, 2000

A favourite. Finished phase 2 trials Probably 3 years before its on the market
Bruce CooperBruce Cooper
Unknown
Unlock Rating
$7.20

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Stressgen Biotechnologies Corp(SSB.TO)

Jul 26, 2005
A lottery ticket! The company has gone into orphan status. Have disappointed investors many, many times. They keep needing money. Very risky.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$0.37

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Stressgen Biotechnologies Corp(SSB.TO)

Nov 12, 2004
Trying to raise $50 million which is equivalent/more than their entire market cap.
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$0.44

Stock price when the opinion was issued

biotechnologypharmaceutical
PAST TOP PICK

Stressgen Biotechnologies Corp(SSB.TO)

Nov 09, 2004
(A Top Pick June 14/04. Down 56%.) They continue to lose money. They'll have to get something through their pipeline quickly that deals with cancer. Doesn't look good.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$0.46

Stock price when the opinion was issued

biotechnologypharmaceutical
TOP PICK

Stressgen Biotechnologies Corp(SSB.TO)

Jun 15, 2004
Holds this stock personally. Risky could double.
Photo of Benj GallanderBenj Gallander
Owned
Unlock Rating
$1.06

Stock price when the opinion was issued

biotechnologypharmaceutical
TRADE

Stressgen Biotechnologies Corp(SSB.TO)

Dec 05, 2003
A field that you have to be really wary of. Many of them have a very high burn rate. Although their trials were fast tracked, this does not necessarily mean continued success.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$1.93

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Stressgen Biotechnologies Corp(SSB.TO)

Dec 04, 2003
Have restructured and will need more money.
Photo of Peter HodsonPeter Hodson
No
Unlock Rating
$2.13

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Stressgen Biotechnologies Corp(SSB.TO)

Oct 07, 2003
Very volatile. Developing a product for HBV (a sexually transmitted disease), which has a large market. In phase two. Has a partnership with Roach and has enough cash to probably last into 2005.
Photo of John Sinkins, CFAJohn Sinkins, CFA
No
Unlock Rating
$2.04

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Stressgen Biotechnologies Corp(SSB.TO)

Jun 30, 2003
On their watch list. Lost a lot of maney last year.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$1.71

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Stressgen Biotechnologies Corp(SSB.TO)

May 14, 2003
A speculative stock. Has to move through the regulatory gateway. Meets a lot of technical resistance at the $1.81 level. Try to pick up near its support level of $1.25.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.78

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Stressgen Biotechnologies Corp(SSB.TO)

May 12, 2003
They are far enough into their trials that investors are now paying more attention. Relatively cheap. Management is OK.
Photo of Peter HodsonPeter HodsonUnlock Rating
$1.90

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Stressgen Biotechnologies Corp(SSB.TO)

Oct 02, 2002
Outlook is quite good and the price is at a good level.
Photo of Mike WeirMike WeirUnlock Rating
$2.45

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Stressgen Biotechnologies Corp(SSB.TO)

Aug 26, 2002
At a good level. Has mad a good agreement with a large pharmaceutical.
Photo of Mike WeirMike WeirUnlock Rating
$3.25

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Stressgen Biotechnologies Corp(SSB.TO)

May 17, 2002
In the final stage of their clinical trials. Will be a couple of years before you know if the product works.
Photo of Bruce CooperBruce CooperUnlock Rating
$4.50

Stock price when the opinion was issued

biotechnologypharmaceutical
WEAK BUY

Stressgen Biotechnologies Corp(SSB.TO)

May 02, 2002
Well along on the approval line. Product seems to be good. The sector is suffering. A higher risk.
Photo of Bruce CooperBruce CooperUnlock Rating
$3.53

Stock price when the opinion was issued

biotechnologypharmaceutical
WAIT

Stressgen Biotechnologies Corp(SSB.TO)

Jan 15, 2002
Fairly risky, but a good risk/reward ratio. In phase 3 trials. Could double if they get into a good partnership.
Photo of Bruce CooperBruce CooperUnlock Rating
$5.50

Stock price when the opinion was issued

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

FCX 0.575$70.705
MU -49.615$1038.375
WDC 37.37$690.9
AAPL 2.3$298.72
SPCX 19.16$211.66

Today's Top Picks

MSFT -7.61$392.15
META 3.94$597.42
BKNG 1.55$176.19
HMP.TO 0$9.76
SPGP 0.13$121.73

Popular Articles

Latest Sell Signals

CRWD -12.785$680.125
MSFT -7.61$392.15
SCCO 1.725$194.945
ADBE 0.515$206.875
PEP -0.15$146.1

Most Recent Experts

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica